- David A. Cory, RPh, MBA, President and Chief Executive Officer, Board Director
- James P. Shaffer, MBA, Chief Business Officer
- Brian Murphy, MD, MPH, MBA, Chief Medical Officer
- Jeffrey S. Glenn, MD, PhD, Director, Founder
- Ingrid C. Choong, PhD, Director, Chemistry
- Curtis L. Scribner, MD, Vice President, Regulatory
- Kevin R. Kaster, JD, Vice President, Patents and Licensing
David Cory is an entrepreneur and industry veteran with 25-years experience in large pharmaceuticals, emerging stage biotechnology, and specialty pharmaceutical organizations with an established track record of operational, transactional, and financial success.
Mr. Cory is currently the President and CEO of Eiger BioPharmaceuticals since 2008. He is responsible for negotiating Eiger’s multiple product licenses from Merck and Astra Zeneca. Cory was previously President and Chief Operating Officer of Prestwick Pharmaceuticals, an Orphan CNS specialty pharmaceutical company, which was acquired by Biovail Pharmaceuticals for $160 million in 2008. Cory was Co-Founder and Chief Commercial Officer at CoTherix, an Orphan Pulmonary Hypertension company, which was acquired by Actelion for $425 million in 2006. Cory began his start up career as Senior Vice President of Commercial Operations at InterMune, a public biotechnology company focused on developing Orphan products for Idiopathic Pulmonary Fibrosis. He was as a key executive in the InterMune IPO, building and managing the company’s commercial organization, in-licensing 4 products and raising over $400 million in the capital markets. Mr. Cory spent the first 12 years of his career in operating positions of increasing responsibility at The Upjohn Company, Glaxo, Glaxo Wellcome, and Glaxo Smith Kline leading teams in CNS, Critical Care, Oncology, Infectious Disease, and Respiratory therapeutic areas, where he directed 10 pharmaceutical product launches and the commercialization of 20 brands.
David Cory is a graduate of the University of Cincinnati, College of Pharmacy, is board certified in Pharmacy, and holds a Masters Degree in Business Administration from the University of Maryland.
James Shaffer brings extensive commercial leadership and business experience with over 20 years of experience with large pharmaceuticals, emerging biotechnology and specialty pharmaceutical companies in Infectious Disease, Neurology, Oncology, GI and Pulmonary Care.
Prior to joining Eiger, Mr. Shaffer served as Vice President and Chief Commercial Officer for Halozyme Therapeutics from 2011 to 2014 where he was responsible for Sales, Marketing and Business Development overseeing the re-launch of Hylenex® and product development in Diabetes and Oncology. From 2011-2014, Mr. Shaffer was Executive Vice President and Chief Commercial Officer responsible for Sales, Marketing, Business Development and Manufacturing with Clinical Data Inc., who developed Viibryd- a unique antidepressant, which was acquired by Forest Labs for $1.2 billion. James was Vice President of Commercial Operations for New River Pharmaceuticals which developed Vyvance® for the treatment of ADHD and was acquired by Shire for $2.6 billion in 2007. From 2004-2007, he was Senior Director of Commercial Operations for Prestwick Pharmaceuticals overseeing the collaboration with Cambridge Labs for Xenazine®, an orphan CNS specialty product, and responsible for the development of the companies commercial capabilities in US and Canada. From 2001-2004, Mr. Shaffer was the National Sales Director for InterMune. James spent the first 10 years of his career in numerous sales and marketing positions of increasing responsibility with Merck and GlaxoSmithKline.
James Shaffer is a graduate of the Ohio State University where he earned a BS degree and Masters Degree in Business Administration.
Dr. Murphy has 15 years experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the Chief Medical Officer of Epiphany Biosciences. Previously, Dr. Murphy was Chief Medical Officer at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then Vice President of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche.
Prior to joining industry, Dr. Murphy was Assistant Professor of Medicine at New York Medical College and was Director of the Clinical Strategies Programs at St. Vincent's Hospital in New York City, the lead hospital of the Catholic Healthcare Network of New York. In addition to patient care and teaching, his research interests focused on the treatment of HIV and the viral hepatitides, including serving on advisory boards, being a clinical trial investigator, making network television appearances and serving as a reviewer for professional publications. Dr. Murphy is board-certified in internal medicine and completed his residency in internal medicine at Tufts-New England Medical Center and served as Chief Medical Resident in the Boston University program. He went on to complete parallel fellowship tracts at Harvard Medical School, one in internal medicine/clinical epidemiology at the Massachusetts General Hospital and the other in medical ethics addressing issues of distributive justice and access to care. He is a member of Alpha Omega Alpha, the national honor medical society.
Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.
Dr. Glenn is an Associate Professor of Medicine, Gastroenterology & Hepatology at Stanford University, and the Director of the Center for Hepatitis and Liver Tissue Engineering.
Dr. Glenn is an author on over 50 scientific articles and book chapters, is an inventor on over 30 issued and pending patent applications, and has been an active consultant for a variety of biotechnology and large pharmaceutical companies. His primary research interest is in molecular virology, with a strong emphasis on translating this knowledge into novel antiviral therapies.
Dr. Glenn’s work has focused on the function and cell biology of the hepatitis C virus (HCV) non-structural proteins, and has identified a collection of novel antiviral targets within HCV that can form the basis for new potential antiviral strategies. Dr. Glenn discovered the role of prenylation in the life cycles of hepatitis delta virus (HDV) and other viruses including as a trigger of virus assembly and a target for a promising antiviral treatment. Other interests include exploitation of hepatic stem cells, development of a small animal model for HCV, and engineered human liver tissues.
Dr. Glenn received his undergraduate degree from the University of California, Berkeley summa cum laude in Biochemistry and French Civilization, and both a PhD in Biochemistry and Biophysics and MD from the University of California, San Francisco Medical Scientist Training Program. Dr. Glenn completed an internship and residency in internal medicine, as well as a fellowship in gastroenterology, at Stanford University's School of Medicine.
Ingrid Choong has 12 years of experience in biotechnology, and most recently served as Group Leader at Sunesis Pharmaceuticals, focusing on developing anti-inflammation and anti-cancer agents. While at Sunesis, Dr. Choong co-led a collaboration with Johnson and Johnson Pharmaceutical Research and Development, resulting in the successful transition of the Cathepsin S program from early discovery into development. In addition, Dr. Choong co-led a second generation small-molecule inhibitor program against cyclin-dependent kinases (CDKs) 2, 7 and 9, as well as several other early discovery-staged small molecule programs.
Dr. Choong did her undergraduate work at the California Institute of Technology in Chemistry and holds a PhD in Chemistry from the University of California, Berkeley.
Dr. Scribner has more than 25 years of drug development and regulatory affairs experience. He spent 11 years at the FDA in the Center for Biologics as a medical officer with wide experience reviewing non-clinical, CMC, clinical, and IND/BLA regulatory systems, including 2.5 years as the Deputy Director of the Office of Blood. He also was the Senior Regulatory Consultant for Quintiles Consulting, Chief Regulatory Office for Intarcia Therapeutics and he is now the Senior Vice President for Medical and Regulatory Affairs for RRD International. Dr. Scribner is a board certified Internist with post-doctorial training in Immunology and Rheumatology at the NIH.
Kevin Kaster has 20 years of experience in biotechnology and large pharma with an established track record of developing effective patent and licensing strategies for important technologies and drug products.
Kevin Kaster most recently served as Vice President Corporate Development for Threshold Pharmaceuticals, a public company focused on developing anti-cancer agents. Previously, Kaster was Vice President Intellectual Property for Kosan Biosciences, a public company acquired by BMS in 2008 with geldanamycin and epothilone anti-cancer agents. Kaster also previously managed the patent portfolios of Geron Corporation (telomerase and human embryonic stem cell technologies) and Affymax/Affymetrix (combinatorial chemistry and DNA chip technologies) as well as the PCR technology patent portfolio of Cetus Corporation. Kaster began his career at Eli Lilly and Company, first as a research scientist and then as a patent technician.
Kevin Kaster is a graduate of the Indiana University School of Law and a graduate of Vanderbilt University with a BS in Chemistry and Molecular Biology.